Phaseline

Companies › Lingyi Biotech

Lingyi Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LY-M001 Injection
rAAV8 vector gene therapy expressing glucocerebrosidase (GCase)
GBAPhase 1Gaucher Disease Type 1Jul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06818838LY-M001 InjectionPhase 1Gaucher Disease Type 1HematologyJul 2027

Targets

GBA (1)

Companies with the same targets

Spur Therapeutics Prevail Therapeutics Azafaros Bial R&D Investments

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.